Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

September 14, 2026

Ascendis Announces Planned $400 Million Share Repurchase Program

September 14, 2026

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

September 9, 2026

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

September 8, 2026

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 7, 2026

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

August 31, 2026

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

August 25, 2026

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

August 13, 2026

Ascendis Pharma Reports Second Quarter 2026 Financial Results

August 6, 2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

August 6, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 33

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© September 2026 Ascendis Pharma